Prognostic model for Acute Respiratory Distress Syndrome using Electrical Impedance Tomography
Electrical Impedance Tomography-Based Prognostic Model for ARDS: A Multicenter, Prospective, Observational Study
This study is trying to see if a new way of measuring lung function can help doctors predict how well patients with Acute Respiratory Distress Syndrome (ARDS) will do and tailor their treatment accordingly.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 625 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 4 sites (Guangzhou, Guangdong and 3 other locations) |
| Trial ID | NCT06967207 on ClinicalTrials.gov |
What this trial studies
This multicenter, prospective, observational study aims to develop and validate a prognostic model for Acute Respiratory Distress Syndrome (ARDS) using Electrical Impedance Tomography (EIT). The study focuses on understanding the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury. By revealing lung injury and heterogeneity, the model seeks to enable risk stratification and guide individualized treatment for patients with ARDS.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-80 who meet the new 2023 ARDS global definition.
Not a fit: Patients expected to die within 24 hours of screening or those with severe comorbidities such as metastatic cancer or chronic respiratory failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could lead to improved risk assessment and personalized treatment strategies for patients with ARDS.
How similar studies have performed: While the approach using EIT for prognostic modeling in ARDS is innovative, similar studies have shown promise in understanding lung injury dynamics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Meet the new 2023 ARDS global definition; 2. Age 18-80 years Exclusion Criteria: 1. Expected death within 24 hours of screening; 2. Metastatic cancer (active malignancy with distant metastases); 3. Severe psychiatric disorders; 4. Pregnancy or postpartum status; 5. Pneumothorax or moderate to large pleural effusion without adequate drainage; 6. Chronic respiratory failure; 7. Patients with pulmonary embolism or pulmonary hypertension; 8. Heart failure patients: EF \<50% or NYHA class III or IV; 9. Patient/family refusal to participate; 10. Participation in another interventional trial within 3 months prior to enrollment
Where this trial is running
Guangzhou, Guangdong and 3 other locations
- Department of Critical Care Medicine, Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
- Department of Critical Care Medicine, Renmin Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)
- Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China Department of — Wuhan, Hubei, China (Recruiting)
- Department of Emergency, Zhongshan Hospital, Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xiaojing Zou Zou
- Email: 249126734@qq.com
- Phone: 84+13995518630
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.